EF-hand domain family member D1Genealiases: MST133 · MSTP133 · PP3051 · SWS2
Q-omics provides the consensus-scored EFHD1 profile across patient tissues and cancer cell-line models. EFHD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EFHD1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, EFHD1 RNA expression shows 21,469 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where EFHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFHD1 survival associations across molecular data types. EFHD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFHD1 RNA expression–survival associations across cancer types. High EFHD1 expression shows unfavorable associations in ACC, SKCM and COAD, but favorable associations in KIRC, KICH and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EFHD1 RNA expression.
This table summarizes EFHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EFHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFHD1 shows lower tumor expression in KIRC, KIRP, COAD, KICH and BLCA and higher tumor expression in BRCA. The KIRC box plot shows higher EFHD1 RNA expression in normal versus tumor tissue (log2 FC = −3.290, t-test p < 0.001).
This table shows molecular features associated with EFHD1 in patient tissues and cancer cell lines. In patient samples, EFHD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EFHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUSC.
